[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","commit":"91a4bba51c","date":"2026-09-10","author":"Jude Gomila","message":"Fourteen orphan products now linked from their targets and cancers (ALK, EGFR, ROS1, ER, FOLR1 inhibitors and tracers; myeloma, prostate, gl","file":"src/data/targets.ts","type":"changed","fields":[{"field":"drugs","after":"[\"ceritinib\", \"brigatinib\", \"ensartinib\"]"}]},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/targets.ts","type":"changed","fields":[{"field":"biology","before":"\"Receptor tyrosine kinase; EML4-ALK fusion is most common. Also in anaplastic large-cell lymphoma and neuroblastoma.\"","after":"\"ALK is a receptor tyrosine kinase; the EML4-ALK fusion is most common. It is also altered in anaplastic large-cell lymphoma and neuroblastoma.\""}]},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/targets.ts","type":"changed","fields":[{"field":"prevalence","after":"[\n      { cancerId: \"nsclc\", pct: \"3-5\", measure: \"Rearrangement\", source: \"https://www.cbioportal.org/study/summary?id=luad_tcga_pan_can_atlas_2018\", note: \"Younger never-smokers\" },\n      { cancerId: \"neuroblastoma\"..."}]}]